Luboshits G - Search Results

1

The effects of stress and transcranial direct current stimulation (tDCS) on working memory: A randomized controlled trial.

Ankri YLE, Braw Y, Luboshits G, Meiron O. Ankri YLE, et al. Among authors: luboshits g. Cogn Affect Behav Neurosci. 2020 Feb;20(1):103-114. doi: 10.3758/s13415-019-00755-7. Cogn Affect Behav Neurosci. 2020. PMID: 31898055 Clinical Trial.

2

Quantification of Drug Release Degree In Vivo Using Antibody-Guided, Dual-NIR-Dye Ratiometric System.

Thankarajan E, Jadhav S, Luboshits G, Gellerman G, Patsenker L. Thankarajan E, et al. Among authors: luboshits g. Anal Chem. 2021 Jun 15;93(23):8265-8272. doi: 10.1021/acs.analchem.1c01104. Epub 2021 Jun 3. Anal Chem. 2021. PMID: 34080851

3

Long-term survival without graft-versus-host-disease following infusion of allogeneic myeloma-specific Vβ T cell families.

Yado S, Luboshits G, Hazan O, Or R, Firer MA. Yado S, et al. Among authors: luboshits g. J Immunother Cancer. 2019 Nov 14;7(1):301. doi: 10.1186/s40425-019-0776-9. J Immunother Cancer. 2019. PMID: 31727148 Free PMC article.

4

Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanoma.

Redko B, Tuchinsky H, Segal T, Tobi D, Luboshits G, Ashur-Fabian O, Pinhasov A, Gerlitz G, Gellerman G. Redko B, et al. Among authors: luboshits g. Oncotarget. 2017 Jan 3;8(1):757-768. doi: 10.18632/oncotarget.12748. Oncotarget. 2017. PMID: 27768593 Free PMC article.

5

Discovery of potent molecular chimera (CM358) to treat human metastatic melanoma.

Gilad Y, Tuchinsky H, Ben-David G, Minnes R, Gancz A, Senderowitz H, Luboshits G, Firer MA, Gellerman G. Gilad Y, et al. Among authors: luboshits g. Eur J Med Chem. 2017 Sep 29;138:602-615. doi: 10.1016/j.ejmech.2017.06.066. Epub 2017 Jun 29. Eur J Med Chem. 2017. PMID: 28710962

6

New somatostatin-drug conjugates for effective targeting pancreatic cancer.

Ragozin E, Hesin A, Bazylevich A, Tuchinsky H, Bovina A, Shekhter Zahavi T, Oron-Herman M, Kostenich G, Firer MA, Rubinek T, Wolf I, Luboshits G, Sherman MY, Gellerman G. Ragozin E, et al. Among authors: luboshits g. Bioorg Med Chem. 2018 Jul 30;26(13):3825-3836. doi: 10.1016/j.bmc.2018.06.032. Epub 2018 Jun 30. Bioorg Med Chem. 2018. PMID: 30017114

7

Tracking the cellular immune response from early premalignancy to active multiple myeloma in a new model.

Jadhav SS, Luboshits G, Bogen B, Firer MA. Jadhav SS, et al. Among authors: luboshits g. Eur J Immunol. 2024 Jan;54(1):e2350627. doi: 10.1002/eji.202350627. Epub 2023 Oct 31. Eur J Immunol. 2024. PMID: 37872778

8

Synthesis of Gold Nanoparticle: Peptide-Drug Conjugates for Targeted Drug Delivery.

Kalishwaralal K, Luboshits G, Firer MA. Kalishwaralal K, et al. Among authors: luboshits g. Methods Mol Biol. 2020;2059:145-154. doi: 10.1007/978-1-4939-9798-5_6. Methods Mol Biol. 2020. PMID: 31435919

9

Discovery of peptide drug carrier candidates for targeted multi-drug delivery into prostate cancer cells.

Bashari O, Redko B, Cohen A, Luboshits G, Gellerman G, Firer MA. Bashari O, et al. Among authors: luboshits g. Cancer Lett. 2017 Nov 1;408:164-173. doi: 10.1016/j.canlet.2017.08.040. Epub 2017 Sep 6. Cancer Lett. 2017. PMID: 28888997

10

Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells.

Kalimuthu K, Lubin BC, Bazylevich A, Gellerman G, Shpilberg O, Luboshits G, Firer MA. Kalimuthu K, et al. Among authors: luboshits g. J Nanobiotechnology. 2018 Mar 30;16(1):34. doi: 10.1186/s12951-018-0362-1. J Nanobiotechnology. 2018. PMID: 29602308 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

25 results

Search Page